Contents & References of Formulation of fast-opening oral tablet of amlodipine 5 mg and investigation of its physicochemical properties
List:
Page
Persian Summary.. 1
Chapter One: Overview
1-1. The necessity and importance of the subject. 3
1-2. Statement of the problem .. 4
1-3. Objectives.. 4
Chapter Two: Review of the literature and studies of others in this field
Part One: Quick-release tablets
1-2. tablet.. 8
2-1-1. Benefits of pills.. 9
2-1-2. Disadvantages of pills.. 10
2-1-3. Types of pills.. 10
2-1-3-1. Oral tablets. 11
2-1-3-2. Tablets used in the oral cavity. 16
2-1-3-3. Tablets that are taken by other means than by mouth. 18
2-1-3-4. Tablets used to prepare solutions. 19
2-1-4. Rapid release tablets. 20
2-1-4-1. Benefits of immediate release tablets. 20
2-1-4-2. Disadvantages of immediate release tablets. 22
2-1-4-3. Important points in the preparation of quick-release tablets. 22
2-1-5. Rapid release tablet formulations. 24
2-1-5-1. Effective ingredients in the formulation of quick-release tablets. 24
2-1-5-2. Excipients in the formulation of quick-release tablets. 24
2-1-5-2-1. Diluents.. 25
2-1-5-2-2. Adhesives.. 26
2-1-5-2-3. Lubricants.. 26
2-1-5-2-4. Dyes.. 27
2-1-5-2-5. Sweeteners. 27
2-1-5-2-6. Flavorings.. 27
2-1-5-2-7. Openers.. 28
2-1-5-2-7-1. Types of openers. 28
2-1-5-2-7-2. New openers. 29
2-1-5-2-7-3. Effective factors in the opening of tablets. 30
2-1-5-2-7-4. Mechanism of action of openers. 31
2-1-6. Methods of producing quick release tablets. 40
2-1-6-1. direct compression.. 40
2-1-6-2. Dry granulation. 40
2-1-6-3. Wet granulation. 41
2-1-7. New technologies for making fast-release tablets. 42
2-1-7-1. Zydis technology.. 42
2-1-7-2. Orasolv technology. 43
2-1-7-3. Durasolv technology. 44
2-1-7-4. Wow tab technology. 45
2-1-7-5. Flashdose technology. 46
2-1-7-6. Flashtab technology. 46
2-1-7-7. Oraquick technology. 46
2-1-8. Physicochemical control tests of quick release tablets. 47
2-1-8-1. The appearance of the tablet. 47
2-1-8-2. Pharmaceutical form uniformity test. 48
2-1-8-3. Weight uniformity test. 48
2-1-8-4. Content uniformity test. 48
2-1-8-5. Difficulty.. 49
2-1-8-6. Erodibility test. 50
2-1-8-7. Open time test. 50
2-1-8-8. Test to determine the amount of active pharmaceutical ingredient. 50
2-1-8-9. Stability test.. 51
Second part: Amlodipine
2-2-1. Mechanism of action.. 53
2-2-2. Drug metabolism and pharmacokinetics. 54
2-2-3. Cases and amount of consumption.. 54
2-2-4. Precautions in use. 55
2-2-5. Contraindications.. 55
2-2-6. Side effects.. 55
2-2-7. Drug interactions.. 55
2-2-8. Recommendations.. 55
Chapter Three: Materials and Methods
3-1. Devices used.. 57
3-2. Materials used.. 58
3-3. Characteristics of some ingredients in the formulation. 59
3-3-1. Sodium croscarmellose.. 59
3-3-2. Cross povidone.. 60
3-3-3. Sodium starch glycolate. 61
3-3-4. Magnesium stearate.. 62
3-3-5. Mannitol.. 62
3-3-6. Microcrystalline cellulose.. 64
3-3-7. sodium saccharin.. 64
3-3-8. Aspartame.. 65
3-3-9. Sodium lauryl sulfate.. 66
3-3-10. Talc.. 66
3-3-11. F-Melt.. 67
3-4. Done works.. 67
3-4-1. Preformulation studies performed on amlodipine powder. 67
3-4-1-1. Examining the organoleptic properties of amlodipine powder. 68
3-4-1-2. Determination of amlodipine powder drop. 68
3-4-1-3. Investigating the compressibility of amlodipine powder. 69
3-4-1-4. Determination of the UV spectrum of amlodipine. 69
3-4-1-5. FTIR spectrum drawing of amlodipine. 69
3-5. Preparation of fast-release oral tablet formulations of amlodipine. 70
3-5-1. Method and preparation of fast-opening oral tablet formulations of amlodipine by direct compression method 70
3-5-1-1. Preparation of fast-opening tablet formulationsPreparation of fast-opening tablet formulations of Amlodipine-Series A. 70
3-5-1-2. Preparation of quick-release tablet formulations of amlodipine-series B. 71
3-5-1-3. Preparation of quick-release tablet formulations of amlodipine-series C. 72
3-6. Physicochemical control tests performed on fast-dissolving tablet formulations. 73
3-6-1. Examining the appearance properties of tablets. 73
3-6-2. Examining the hardness of tablets. 73
3-6-3. Examining the erodibility of tablets. 73
3-6-4. Determination of thickness and diameter of tablets. 74
3-6-5. Checking the uniformity of the weight of tablets. 74
3-6-6. Tablet opening time tests. 74
3-6-7. Standard graph of amlodipine at 239 nm in HClo.1N medium. 74
3-6-8. Determination of the amount of amlodipine. 75
3-6-9. Dissolution test and drug release method. 75
3-6-10. Taste test on superior formulation. 76
Chapter Four: Results
4-1. The results of pre-formulation studies conducted on amlodipine powder. 79
4-1-1. The results of examining the organoleptic characteristics of amlodipine powder. 79
4-1-2. Results related to the determination of amlodipine powder spillage. 79
4-1-3. The results related to the compressibility of amlodipine powder. 81
4-1-4. The results related to the UV spectrum of amlodipine powder in 0.1 NHCl environment. 82
4-1-5. Results related to FTIR spectrum of amlodipine powder. 83
4-1-6. Results related to determining the amount of amlodipine tablets. 84
4-1-7. General conclusion of the studies conducted on amlodipine powder. 85
4-2. Results related to formulations and physicochemical control of amlodipine fast-release tablets. 85
4-2-1. The results of the physicochemical control tests on Amlodipine formulations - Series A 86
4-2-2. The results of physicochemical control tests on amlodipine formulations - B series 86
4-2-3. The results of physicochemical control tests on amlodipine formulations - C 87 series
4-2-4. The results of the taste test on the selected formulation (D series formulations). 88
4-3. Results from the dissolution of superior formulations. 89
Chapter Five: Discussion and Conclusion
5-1. Discussion and conclusions related to formulations and physicochemical control of quick-release tablets of amlodipine by direct compression method. 93
5-2. General conclusion regarding better formulation by direct compression method. 94
5-3. Study of sweetener in quick-opening tablets of amlodipine by direct compression method. 94
English abstract. 95
Resources
Source:
1) Collette D.M. Pharmaceutical preparations. In: Collete D.M., Aulton MG. Pharmaceutical practice. Edinburgh: Living stone; 1990. p. 145-156.
2) Katzung, Bertram. Basic and clinical pharmacology. Translated by Mehrnaz Razvanfard. Tehran: Andisheh Rafi; 2019. Volume I. pp. 231,232.
3) Katzung, Bertram. Basic and clinical pharmacology. Translated by Mehrnaz Razvanfard. Tehran: Andisheh Rafi; 2019. Volume I. p. 211. 4 (Bazsafid, Sara "Formulation and Physicochemical Control of Ibuprofen Effervescent Tablets" Ph.D. Dissertation of Pharmacy, Shahid Beheshti University of Medical Sciences, Tehran: p. 84, 80, 74, 72.
5) Guad RS, Gupta D. Practical pharmaceutics ed. India: CBS publications and distributions 2002 p. 242-249.
6) Ketani, Saba "Formulation of carbamazepine 100 mg fast-release oral tablet and investigation of its physicochemical properties" PhD Thesis of Pharmacy, Islamic Azad University, Department of Pharmaceutical Sciences, Tehran; 1389-1990 pp. 59-9.
7) Ansel H.C. Oral solids and tablets. In: Ansel H.C. Pharmaceutical dosage forms and drug delivery systems. The ed. Philadel-phia: loppincot willicus and wilknis: 2000.p.164-228.
8) Collete D.M. Pharmaceutical preparations. In collete D.M., Aulton MG. Pharmaceutical practice. Edinburgh: Living stone; 1990. p.145-156.
9) Benker G.S, Peck G.E. Tablet formulation and design in: Liberman H.A and lechman L. Pharmacopeia Dosage form: tablets. ed. New York: Marcel Dekker; 1990. p. 369-417.
10) Narin J.G. Solution emulsion suspensions and extracts. In Gennaro A.R. Remington the science and practice of pharmacy. 20th ed. Pennsylvania: Mack publishing company; 2000.p.721-752.